Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

BioMAP® Profiling Provides Insights into Toxicity of Nanomaterials, Failed Drugs and Environmental Chemicals

Published: Monday, March 19, 2012
Last Updated: Monday, March 19, 2012
Bookmark and Share
ToxCast high-throughput screening results using BioSeek’s BioMAP® human primary cell assay systems presented at society of toxicology.

Assessments of the biological activity of various nanomaterials and chemicals in the context of primary human cell biology were presented at the annual meeting of the Society of Toxicology by scientists from the U.S. Environmental Protection Agency and BioSeek, LLC.

The presented findings further demonstrate the value of BioMAP® human primary cell assay systems for both identifying critical bioactivities and potentially adverse effects of drugs, new materials and other compounds in a high-throughput format.

“Through our work with EPA, BioMAP is yielding a rich harvest of biological information on a wide variety of environmental and other chemicals and their potential effects on human health,” said Ellen Berg, Ph.D., General Manager of BioSeek.

Berg continued, “In addition to helping meet the goals of the ToxCast Program, which are aimed at developing high-throughput screening methods capable of predicting chemical toxicities, this information is continuing to enrich our BioMAP database. We view that resource as an increasingly valuable tool that can be mined to better understand the activities and potential safety of our pharmaceutical partners’ compounds in the context of human biology, prior to undertaking costly human clinical trials.”

In an oral presentation by EPA, various nanomaterials with varying cores and their ion and micro counterparts were tested for cytotoxicity in various cell types, for transcription factor activation in HepG2cells, and for protein bioactive profiling in eight BioMAP human primary cell systems at concentrations equivalent to human exposures of 24 hours to 45 years.

Analysis showed that nanomaterial cores are critical to bioactivities and their effects are often similar to those of related ions.

Comparing test results on nanomaterials to reference profiles of other compounds in the BioMAP database suggested further molecular targets and pathways affected by the tested nanomaterials that weren’t directly measured by the assays performed.

A poster presented by EPA and BioSeek collaborators discussed the biological profiling of the ToxCast Phase II Chemical Library in BioSeek’s primary human cell co-culture systems.

The Phase II library contains 1060 unique compounds including failed pharmaceuticals donated by industry partners, reference compounds known to be endocrine disrupters, carcinogens or reproductive/developmental toxicants, and other widely used chemicals, food and cosmetic additives, and proposed alternatives to current industrially used chemicals.

The chemicals were tested in a panel of BioMAP co-culture systems and classified based on their ability to cause overt cytotoxicity in various cells types and on their bioactivity profiles when compared to reference compounds.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Asterand’s Subsidiary BioSeek Extends Collaboration with Merck Serono
New three-year deal provides Merck Serono expanded access to BioSeek LLC’s BioMAP® platform.
Thursday, March 29, 2012
BioSeek and EPA Expand ToxCast™ Contract
BioMAP® Systems technology to profile the biological effects of compounds in a second phase of the agency’s ToxCast™ program.
Monday, July 06, 2009
BioSeek Licenses Two Novel Anti-Inflammatory Peptides
The two peptides, licensed from Amylin Pharmaceuticals, were identified as candidates for development in ongoing research collaboration between the two companies.
Friday, November 14, 2008
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos